Seoul-based Lunit will collaborate with Microsoft to scale its AI-powered cancer diagnostics globally, with a strong focus on the U.S. market.
As part of the partnership, Lunit will integrate with Microsoft Azure to deliver scalable, cloud-based cancer detection tools. The two companies are codeveloping a service that allows hospitals to fine-tune AI models using their own clinical data, which could help address challenges in cross-site model performance, the company said. In addition, Lunit will build workflow automation tools using Microsoft’s agentic AI frameworks.
The collaboration follows Lunit’s acquisition last year of Volpara, and is a step for Lunit beyond standalone AI products toward integrated, enterprise-ready offerings, the company noted.
